Sign In

Steven Dickman

Owner, CBT Advisors

Steven Dickman is the Founder and CEO of CBT Advisors, a consulting firm specializing in the life sciences and biotechnology sectors. His expertise spans venture capital, biomedical science, and science journalism. He has a notable background in biochemistry research, having worked at prestigious institutions such as Princeton University and the German Cancer Research Center. Additionally, he has contributed articles to leading scientific journals, including Nature and Science.

Before establishing CBT Advisors in 2003, Dickman served as a Principal at Techno Venture Management, where he evaluated numerous investment opportunities in tools, therapeutics, and diagnostics. His firm provides strategic consultancy services, including market analysis and due diligence for clients in the biotech and pharmaceutical industries.123

Highlights

Aug 27 · linkedin

I'm speaking at #SBW2024— a FREE conference designed to bring the entire #Boston and #NewEngland startup community together! #Biotech #MedicalDevice #IPO

100+ sessions featuring founders, startup teams, and ecosystem supporters from every industry.

I’m especially excited to be part of the crossover / IPO session at Suffolk U. (or virtually) on Tues. Sep. 10th at 3:45pm ET along with Julie Feder Aura Biosciences @JamesSchneider Cooley LLP and moderator Danielle O’Neal Banc of California

Free ticket here: ➡️https://lnkd.in/erjWSTRU

Jun 12 · linkedin

I really enjoyed co-moderating with Jay Olson of Oppenheimer & Co. Inc. the Corporate Development workshop at the Obesity & Weight Loss Drug Development Summit today in Boston put on by Hannah Barry and Hanson Wade Group. Excellent audience participation and great #obesity market insights from Jay.

Key learnings included:

-- The overall obesity therapeutics market is going to reach $100 billion in less than 10 years according to the Wall Street consensus -- Average annual price actually paid in the United States for Wegovy (Novo Nordisk) & Zepbound (Eli Lilly and Company) for weight loss is $9,000; in overseas markets e.g. Europe it is closer to $4,000 -- This pricing, while heavily questioned by some political leaders, if taken up and reimbursed by insurers will actually enable society to reduce healthcare spending on a variety of co-morbidities including not just heart attacks and strokes but also hip & knee replacements, sleep apnea and liver fibrosis among many others -- There were at least 124 drug candidates in clinical development for obesity as of January - probably more now -- It is a big question what will happen when reimbursement (such as it is) runs out for the first cohort of patients currently taking anti-obesity medications -- If GLP-1 agonists follow the pattern of PD-1 antibodies (in oncology), new market entrants can still grab significant market share -- Any successful 2024 sales pitch for an obesity candidate (using any mechanism) must address not only the approach and the results but also the potential for combinability (e.g. with GLP-1s) and the path to likely reimbursement

#Weightloss #Wegovy #Zepbound #Novo #EliLilly #biotech #drugdiscovery #drugdevelopment

Related Questions

What are some notable projects Steven Dickman has led at CBT Advisors?
How did Steven Dickman transition from science journalism to venture capital?
What is the Boston Biotech Watch blog about?
Can you provide examples of Steven Dickman's publications in Nature and Science?
What are the main services offered by CBT Advisors?
Steven Dickman
Steven Dickman, photo 1
Steven Dickman, photo 2
Add to my network

Location

Cambridge, Massachusetts, United States